Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures turns negative

Q1 FY2026 capital expenditures was -$13K, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$115K. Over 3 fiscal years it compounded at -82.8% a year.

Context

  • Capital expenditures amounted to 0.3% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly capital expenditures holds near -$13K or moves back toward the trailing-twelve-month quarterly average of -$28.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13K-7.1% QoQ
Last fiscal yearDec 2025
-$102K-61.8% YoY
LTMMar 2026
-$115K-56.9% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-61.8%——
3-year CAGR-82.8%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(102K) USD
Year-over-year change
+61.8%

Capital Expenditures vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -56.9% is the 7th highest of 11, against a peer median of -39.2%.
  • Capital expenditures amounts to 0.3% of revenue for SGMO, versus a peer median of 3.9%.
SGMO Competitors
Capital Expenditures for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$3.49M USD+602.4%-9.8%179.1%
CDXSCodexis, Inc.LTM Mar 2026$3.39M USD-23.5%-18.7%4.3%
IVVDInvivyd, Inc.LTM Mar 2026$737K USD+411.8%-55.0%1.3%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$671K USD+272.8%-52.0%1.9%
OABIOmniAb, Inc.LTM Mar 2026$523K USD-54.8%-68.0%1.8%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$506K USD-70.7%-37.4%17.1%
MOLNMolecular Partners AGLTM Mar 2026CHF 333.55K CHF-67.9%-20.4%—
IPHAInnate Pharma S.A.FY2025€134.47K EUR-65.6%-50.7%4.8%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$115K USD-56.9%-82.8%0.3%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$68.98K USD+76.9%+3.5%3.9%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$52K USD-82.7%-62.1%1.6%
Peer median (excluding SGMO) —-39.2%-44.1%3.9%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(178.3M)(192.28M)(257.83M)(97.94M)(122.93M)
Depreciation & Amortization17.64M20.56M22.19M9.36M7.6M
Deferred Income Tax2.77M0(6.34M)00
Stock-Based Compensation32.96M31.65M27.36M12.38M9.08M
Change in Working Capital(101.9M)(82.32M)(164.03M)4.51M(4.22M)
Accounts Receivables(789K)2.34M(976K)953K155K
Inventory7.66M0000
Accounts Payables(7.66M)13.35M5.59M(14.17M)2.79M
Other Working Capital(101.11M)(98M)(168.65M)17.72M(7.17M)
Other Non-Cash Items(6.43M)(1.24M)153.8M4.55M13.27M
Operating Cash Flow(233.25M)(223.63M)(224.84M)(67.14M)(97.21M)
Capital Expenditures(23.28M)(20.17M)(21.16M)(267K)(102K)
Acquisitions (Net)(119K)(79.46M)01.95M0
Purchases of Investments(338.16M)(277.39M)(59.55M)00
Sales of Investments609.76M356.85M234.24M35.84M0
Other Investing Activities079.46M000
Investing Cash Flow248.2M59.29M153.53M37.52M(102K)
Debt Repayment00000
Common Stock Issued27.1M84.87M15.11M28.99M74.01M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.76M(209K)(518K)(614K)(3.26M)
Financing Cash Flow32.86M84.66M14.59M28.38M70.75M
Effect of Forex Changes(263K)1.25M1.48M(2.05M)4.09M
Net Change in Cash47.54M(78.43M)(55.24M)(3.29M)(22.47M)
Free Cash Flow(256.53M)(243.8M)(246M)(67.41M)(97.31M)

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.